# CRISPR & Gene-Editing Therapies: State of the Field (October 2026)

Research dossier · v1 · updated 2026-10-30 · 3,638 words · 52 sources · 27 claims · verification: verified

Covers CRISPR-Cas9 nuclease therapies, base and prime editors, the delivery systems that decide which tissues can be edited, and the safety questions that dominate current debate. The most important takeaway: the first approved CRISPR therapy is an ex vivo product for hemoglobinopathies, while in vivo, bespoke and prime-editing programs remain mostly in early or pivotal trials with unresolved long-term safety.

## Contents

- Executive summary
- Background and core concepts
- Timeline of key milestones
- State of the art
  - Ex vivo nuclease editing: exa-cel
  - In vivo LNP-delivered editing
  - Base editing
  - Prime editing
  - Edited immune cells
  - Quantitative benchmarks
- Open problems and active debates
- Major programs and players
- Outlook: what to watch (next 12-18 months)
- Key papers
- Glossary

## Sample findings

- CRISPR-Cas systems are prokaryotic adaptive immune systems whose guide-programmed nucleases were repurposed as genome-editing tools.
- Base editors and prime editors modify DNA without the double-strand break that Cas9 nuclease editing relies on.

## Get the full dossier

GET https://space-kitty.com/api/v1/dossiers/gene-editing-therapies costs $0.20 via x402 (USDC on Base Sepolia (testnet)). Send `Accept: text/markdown` for Markdown or `application/json` for structured data (claims with citations, timeline, benchmarks, open problems, glossary, bibliography).
---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.